NEW DELHI : Hyderabad-based pharmaceutical firm Biological E. has received the Drugs Controller General of India's (DCGI) approval to conduct two clinical trials-- one in adults and the other in children and adolescents --for its covid-19 vaccine candidate Corbevax, the Department of Biotechnology (DBT) said on Friday. “Biological E.
has received Drugs Controller General of India (DCGI) approval for conducting Phase III Comparator Safety & Immunogenicity trial in adults after Subject Expert Committee’s (SEC) review of Phase I and II clinical trials data," the Ministry of Science & Technology said.
The company also received approval on 1 September to initiate aPhase II/III study to evaluate "safety, reactogenicity, tolerability and